Weber JS, Carlino MS, Khattak A, Meniawy T, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 2024 Jan 18:S0140-6736(23)02268-7. doi: 10.1016/S0140-6736(23)02268.
PMID: 38246194